Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …

Background Injectable luteinizing hormone–releasing hormone agonists (eg, leuprolide) are
the standard agents for achieving androgen deprivation for prostate cancer despite the initial …

Background Men using cholesterol-lowering statin medications have been found to have
lower risks of both advanced and fatal prostate cancer in multiple registry-based studies and …

Background: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH)
antagonists compared with GnRH agonists in men with prostate cancer and known …

Importance Cardiovascular disease is a leading cause of mortality in patients with prostate
cancer, and androgen deprivation therapy (ADT) may worsen cardiovascular risk …

Background Although androgen deprivation therapy (ADT) is associated with cardiovascular
risks, the extent and temporal trends of cardiovascular burden amongst patients with …

Opinion statement Prostate cancer is the second leading cause of cancer death in men, and
cardiovascular disease is the number one cause of death in patients with prostate cancer …

Background Cardiovascular disease (CVD) incidence is higher in men with prostate cancer
(PC) than without. Objectives We describe the rate and correlates of poor cardiovascular risk …

Background: The etiology of benign prostatic hyperplasia and prostate cancer are unknown,
with ageing being the greatness risk factor. Methods: This new perspective evaluates the …

Abstract Purpose of Review Prostate cancer (PCa) is amongst the most common cancers in
men worldwide. Cardiovascular (CV) risk factors and CV disease (CVD) are common …